Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma.
作者信息
Khoury Rita, Khalife Nadine, Ibrahim Rebecca, Saleh Khalil
机构信息
International Department, Gustave Roussy Cancer Campus, Villejuif, France.
Head and Neck Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.
出版信息
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):923-926. doi: 10.21037/hbsn-23-476. Epub 2023 Nov 15.
Abstract
摘要
相似文献
1
Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma.
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):923-926. doi: 10.21037/hbsn-23-476. Epub 2023 Nov 15.
2
Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
Cureus. 2023 Oct 10;15(10):e46792. doi: 10.7759/cureus.46792. eCollection 2023 Oct.
3
Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.
4
Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
J Natl Compr Canc Netw. 2022 Apr 4;20(5):430-435. doi: 10.6004/jnccn.2021.7121.
5
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Expert Opin Investig Drugs. 2022 Jan;31(1):125-131. doi: 10.1080/13543784.2022.2017882. Epub 2022 Jan 7.
6
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Acta Pharm. 2024 Mar 30;74(1):1-36. doi: 10.2478/acph-2024-0005. Print 2024 Mar 1.
7
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Expert Opin Investig Drugs. 2021 Apr;30(4):463-477. doi: 10.1080/13543784.2021.1900821. Epub 2021 Apr 11.
8
Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report.
Onco Targets Ther. 2024 Jun 13;17:489-496. doi: 10.2147/OTT.S434449. eCollection 2024.
9
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
Pharmacoeconomics. 2023 Mar;41(3):307-319. doi: 10.1007/s40273-022-01227-6. Epub 2022 Dec 28.
10
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.
Cancers (Basel). 2021 Apr 3;13(7):1706. doi: 10.3390/cancers13071706.
本文引用的文献
1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
2
Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.
3
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475.
4
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
5
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
6
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Cancer Sci. 2023 Feb;114(2):574-585. doi: 10.1111/cas.15486. Epub 2022 Dec 4.
7
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Br J Cancer. 2021 Mar;124(5):880-892. doi: 10.1038/s41416-020-01157-0. Epub 2020 Dec 3.
8
Clinicogenomic Analysis of -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Cancer Discov. 2021 Feb;11(2):326-339. doi: 10.1158/2159-8290.CD-20-0766. Epub 2020 Nov 20.
9
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Ann Oncol. 2020 Oct;31(10):1405-1412. doi: 10.1016/j.annonc.2020.06.018. Epub 2020 Jul 2.
10
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
Zotero 插件